What is the difference between MOTS-c and AOD-9604?

MOTS-c: MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA, discovered by Lee and Cohen at USC in 2015 (sequence: MRWQEMGYIFYPRKLR). It is an investigation... AOD-9604: AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the C-terminal fragment of human growth hormone (residues 177-191) with an additional N-terminal tyrosine. Developed by Metabolic Pharmac...

MOTS-c vs AOD-9604

Q: Can you stack MOTS-c and AOD-9604?

MOTS-c (metabolic) and AOD-9604 (metabolic) are in the same category and may have overlapping mechanisms — researchers should review both profiles carefully before combining. Consult a licensed provider before combining any compounds.

Head-to-head comparison of MOTS-c and AOD-9604 — mechanism, dosing, side effects, legal status, and pricing.

MOTS-c

MOTS-c is a 16-amino-acid mitochondrial-derived peptide (MDP) encoded within the mitochondrial 12S rRNA, discovered by Lee and Cohen at USC in 2015 (sequence: MRWQEMGYIFYPRKLR). It is an investigational, research-only peptide studied as a metabolic regulator; it has not been approved by the FDA for any indication.

Profile Prices Calculator

AOD-9604

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to the C-terminal fragment of human growth hormone (residues 177-191) with an additional N-terminal tyrosine. Developed by Metabolic Pharmaceuticals (Australia) to isolate a purported 'lipolytic' activity of GH without GH-receptor-mediated growth or diabetogenic effects. AOD-9604 is NOT FDA-approved for any indication; controlled human trials for obesity did not demonstrate clinically meaningful weight loss, and obesity development was terminated in 2007.

Profile Prices Calculator

MOTS-c

AOD-9604

Category

Metabolic

Legal Status

Research Only

Mechanism

MOTS-c acts primarily in skeletal muscle, where it activates AMPK — in part via inhibition of the folate cycle and de novo purine biosynthesis leading to AICAR accumulation — increasing glucose uptake and fatty acid oxidation. Interaction with the folliculin–FNIP complex has been proposed. An endocrine role is also reported, with serum MOTS-c levels declining with age, obesity, and type 2 diabetes.

The original preclinical hypothesis was that hGH(177-191) retains a lipolytic activity via a non-GH-receptor pathway, with some rodent data implicating β3-adrenoceptor expression and cAMP signaling in adipocytes. This mechanism is disputed and has not been robustly reproduced in controlled human studies — Phase 2 trials showed no significant effect on body weight versus placebo. AOD-9604 does not measurably raise serum IGF-1 and does not impair glucose tolerance in human safety studies, which is consistent with lack of GH-receptor agonism but does not establish clinical lipolytic efficacy.

Dose Range

10 mg

250–500 mcg

Route

SubQ

Frequency

2–3 times per week

Once daily

Dosing Notes

Grey-market research protocols typically use ~10 mg subcutaneously 2–3 times per week. This dosing is not clinically validated and is not supported by any completed, successful human trial of native MOTS-c.

No clinically validated dose exists for any human indication. Community/grey-market protocols typically use 250–500 mcg (commonly 300 mcg) SubQ once daily, often in the morning fasted, for 8–12 week cycles. These protocols are extrapolated from abandoned clinical development doses and are not supported by positive efficacy data.

Side Effects

Limited human safety data for native MOTS-c
Injection-site reactions (anecdotal)
Theoretical concerns from AMPK activation and altered mitochondrial signaling
No serious adverse events reported in the Phase 1a/1b study of the analog CB4211, but that program was discontinued and native MOTS-c has not been systematically evaluated in humans

Injection site reactions — redness, soreness
Headache
Overall adverse-event rate in Phase 1/2 trials was indistinguishable from placebo
Long-term safety in chronic non-clinical use is unknown

Contraindications

Pregnancy or breastfeeding
Known hypersensitivity
Active malignancy (effects of AMPK modulation on tumor metabolism are context-dependent and not characterized in humans)
Insufficient human safety data prevents definitive contraindications

Pregnancy and breastfeeding (no human data)
Known hypersensitivity to the peptide or excipients
Active malignancy (theoretical caution, extrapolated from GH-axis agents despite lack of IGF-1 effect)
Not established as effective for weight loss — GLP-1 receptor agonists have far stronger evidence

MOTS-c Research Summary

Evidence is largely preclinical. The modified MOTS-c analog CB4211 (CohBar) completed a Phase 1a/1b study in healthy volunteers and obese NAFLD subjects with mixed exploratory readouts; CohBar subsequently divested from the MOTS-c program and wound down in 2023, so no Phase 2 or Phase 3 data exist. Native MOTS-c has no completed clinical trials demonstrating efficacy in humans.

Key references

AOD-9604 Research Summary

Preclinical: Ng et al. (Horm Res 2000) and Heffernan et al. (Int J Obes 2001; Endocrinology 2001) reported reduced body weight gain and increased fat oxidation in rodent models. Clinical: Six randomized, double-blind, placebo-controlled Phase 1/2 trials across ~900 subjects established a safety profile indistinguishable from placebo (Stier et al., J Endocrinol Metab 2013) but did NOT demonstrate clinically meaningful weight loss; a 24-week Phase 2b trial (~536 subjects) failed its primary efficacy endpoint and obesity development was terminated in 2007. Later preclinical work explored intra-articular use in a rabbit osteoarthritis model (Kwon & Park 2015); no adequately powered human OA trial has been published. Regulatory: AOD-9604 is NOT FDA-approved. It was placed on the FDA interim 503A Category 2 list (may present significant safety risk) in 2023, removed from Category 2 in September 2024 after the nominator withdrew, and at the December 4, 2024 PCAC meeting the committee voted AGAINST inclusion on the 503A Bulks List. Widely sold for 'weight loss' and osteoarthritis via grey-market and compounding channels without adequate human efficacy data.

Key references

Can you stack MOTS-c and AOD-9604?

MOTS-c and AOD-9604 are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.

Other comparisons

BPC-157 vs TB-500 Semaglutide vs Tirzepatide Ipamorelin vs CJC-1295 CJC-1295 vs Sermorelin Semaglutide vs Liraglutide Selank vs Semax BPC-157 vs GHK-Cu MK-677 vs Ipamorelin

This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.

MOTS-c

AOD-9604

AOD-9604 Research Summary

Can you stack MOTS-c and AOD-9604?